We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The UK Competition and Markets Authority (CMA) has accused Canadian pharma company Concordia International of abusing its dominant position by increasing the price of a thyroid drug by about 6,000%.
Concordia International, the Canadian drug company, has overcharged the NHS by more than £100m in the past decade for a life-changing thyroid drug, according to Britain’s competition watchdog.